Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcq

Showing results (231-240 of 267) with videos related to

Pageof 27
Sort By:
European Urology Oncology|January 23, 2026
Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective StudyGarvey Mezepo, Zine-Eddine Khene, Jihane Boustani, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 12, 2025
Enhanced Recovery After Surgery for patients undergoing radical cystectomy: Surgeons' perspectives and recommendations ten years after its implementationSimone Albisinni, Luca Orecchia, Georges Mjaess, et al.
Nature Communications|April 23, 2026
Multiomics immune profiling of a patient-relevant orthotopic lung cancer model using SEPARATE-SeqPauline M R Bardet, Lize Allonsius, Eva Hadadi, et al.
European Urology Oncology|February 20, 2026
Real-world Adherence to European Association of Urology-recommended Non-muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological OutcomesMattia Longoni, Pietro Scilipoti, Mario De Angelis, et al.
BJU International|May 22, 2025
Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre studyMattia Longoni, Pietro Scilipoti, Mario De Angelis, et al.
BJU International|January 11, 2025
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group resultsPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Actas Urologicas Espanolas|February 14, 2025
The impact of a multidisciplinary approach on treatment decisions and outcomes in urothelial carcinoma: A systematic reviewE Albers Acosta, L Pelari-Mici, G Celada Luis, et al.
Targeted Oncology|November 13, 2024
Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysisTakafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, et al.
European Urology Focus|June 21, 2024
Machine Learning and External Validation of the IDENTIFY Risk Calculator for Patients with Haematuria Referred to Secondary Care for Suspected Urinary Tract CancerSinan Khadhouri, Artsiom Hramyka, Kevin Gallagher, et al.
BJU International|March 12, 2024
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancerMarkus von Deimling, Laura S Mertens, Marc Furrer, et al.
Pageof 27

Showing results (231-240 of 267) with videos related to

Sort By:
Pageof 27
European Urology Oncology|January 23, 2026
Oncological Outcomes of Trimodal Therapy in Primary Versus Secondary Muscle-invasive Bladder Cancer: A Multicenter Retrospective StudyGarvey Mezepo, Zine-Eddine Khene, Jihane Boustani, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|January 12, 2025
Enhanced Recovery After Surgery for patients undergoing radical cystectomy: Surgeons' perspectives and recommendations ten years after its implementationSimone Albisinni, Luca Orecchia, Georges Mjaess, et al.
Nature Communications|April 23, 2026
Multiomics immune profiling of a patient-relevant orthotopic lung cancer model using SEPARATE-SeqPauline M R Bardet, Lize Allonsius, Eva Hadadi, et al.
European Urology Oncology|February 20, 2026
Real-world Adherence to European Association of Urology-recommended Non-muscle-invasive Bladder Cancer Management: From Evidence-based Practice to Oncological OutcomesMattia Longoni, Pietro Scilipoti, Mario De Angelis, et al.
BJU International|May 22, 2025
Contemporary outcomes in non-muscle-invasive bladder cancer: a large European multicentre studyMattia Longoni, Pietro Scilipoti, Mario De Angelis, et al.
BJU International|January 11, 2025
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group resultsPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
Actas Urologicas Espanolas|February 14, 2025
The impact of a multidisciplinary approach on treatment decisions and outcomes in urothelial carcinoma: A systematic reviewE Albers Acosta, L Pelari-Mici, G Celada Luis, et al.
Targeted Oncology|November 13, 2024
Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysisTakafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, et al.
European Urology Focus|June 21, 2024
Machine Learning and External Validation of the IDENTIFY Risk Calculator for Patients with Haematuria Referred to Secondary Care for Suspected Urinary Tract CancerSinan Khadhouri, Artsiom Hramyka, Kevin Gallagher, et al.
BJU International|March 12, 2024
The optimal number of induction chemotherapy cycles in clinically lymph node-positive bladder cancerMarkus von Deimling, Laura S Mertens, Marc Furrer, et al.
Pageof 27